Cosette Pharmaceuticals Announces the launch of Griseofulvin Oral Suspension, 125 mg/5 mL.

06 Dec 2022
www.biospace.com
Drug Approval
Launch Enables Access To Patients And Providers, Alleviating Supply Chain Constraints BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cosette Pharmaceuticals, Inc ("Cosette") began shipping Griseofulvin Oral Suspension, 125 mg/5 mL (0713-0850-04) into all channels in the United States. This press release features multimedia. View the full release here: Apurva Saraf, President and CEO, Coesette Pharmaceuticals. (Photo: Business Wire) This launch will provide much needed access to patients and providers for a product which has been supply constrained. The finished product will be manufactured in the United States. Apurva Saraf, President and CEO of Cosette Pharma, stated, "This approval and immediate launch demonstrates our ability to continue transforming Cosette, by launching important products through our drug development, supply chain management and manufacturing expertise. This is in addition to a long list of new product launches this year, and is a testament to how we are Innovating Every Day." According to IQVIA™, U.S. market annual sales for the 12 months ended October 2022 for Griseofulvin Oral Suspension, 125 mg/5 mL is estimated to be approximately $12 million. See the Full Prescribing Information and Instructions for Use for Griseofulvin Oral Suspension, 125 mg/5 mL. About Cosette Pharmaceuticals, Inc.: Cosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. The current products focus on complex dosage forms including topical creams, ointments, oral liquids/solutions, suppositories, and injectables. Cosette has a long history of quality manufacturing, consistent supply, and commercialization success, including two sites (New Jersey and North Carolina) supported by more than 350+ dedicated employees across all functional areas. Cosette has a fast-growing portfolio of branded pharmaceuticals, consisting of products in cardiology, women’s health and pediatrics. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm. Follow us on LinkedIn. View source version on businesswire.com: Contacts Serge Ilin-Schneider: bd@cosettepharma.com Kian Kazemi: sales@cosettepharma.com Source: Cosette Pharmaceuticals, Inc. Smart Multimedia Gallery Photo Apurva Saraf, President and CEO, Coesette Pharmaceuticals. (Photo: Business Wire) Photo Griseofulvin Oral Suspension 125mg-5mL. (Photo: Business Wire) Logo View this news release and multimedia online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.